AI/Automation. Right time for your company to start the journey

Artificial intelligence could acclaim a new era for drug development however forethought continues about how revolutionary its touch will actually be. End Quote

Atlantic City, NJ (1888PressRelease) September 30, 2017 - The recent deal from the Top 10 Pharma MNC ($43m deal with British Artificial intelligence firm) may signal a revolution for drug development that could accelerate the drug discovery process, helping patients in urgent need of specialized treatments. Also many other players looking at investments in the AI arena on the expectation those AI solutions are braced to shape new the biopharma industry.

In the similar manner that the financial sector has engaged physicists and mathematicians to originate prognostic software to tweak trading decisions, many professionals foretell that Life sciences industry will be particularly centripetal to Artificial intelligence (AI) solutions as its inherent stranding in science, design and invention.

Artificial intelligence (AI) for discovery, development and regulatory challenges
The punctilious nature of pharma research and development means that drug discovery – bringing a new drug tomarket once a lead compound has beendiscovered – can take more than 10 years.The development of a single molecule can often cost more than $1bn because of inefficiencies in the sampling process and the vast numbers of screenings that generally required – fewer than 1 in 10 molecules that enter the discovery phases actually fetch up being taken to market.

Currently, some pharma majors using AI solutions to filter out difficult-to-find molecules in the drug discovery phases to expedite the development of treatments in a number of therapeutic areas. It could result in significantly shorten development times and brings down the prices – as screenings will be mainly substituted by super computer and prognosticative algorithms or models.

Clinical stages could benefit from AI algorithms inrespects to clinical trial design, site selection and subjects enrolment. Adverse events (AE) can be better auspicated with the help of AI solutions. Machine learning (ML) and analytics can accelerate the examination of clinical trial data. These combinations could also advance Pharmacovigilance measures, further down the drug discovery process.

###

space

Other Related Press Releases